$GH
Guardant Health, Inc.

2023 Q3 Form 10-Q Financial Statement

#000157628023000123 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $143.0M $137.2M
YoY Change 21.83% 25.66%
Cost Of Revenue $57.60M $53.85M
YoY Change 42.24% 46.62%
Gross Profit $85.40M $83.30M
YoY Change 11.04% 15.03%
Gross Profit Margin 59.71% 60.74%
Selling, General & Admin $105.1M $112.6M
YoY Change -13.48% -4.03%
% of Gross Profit 123.08% 135.12%
Research & Development $93.85M $90.36M
YoY Change -6.16% 5.74%
% of Gross Profit 109.9% 108.47%
Depreciation & Amortization $10.30M $10.63M
YoY Change 13.19% 31.25%
% of Gross Profit 12.06% 12.76%
Operating Expenses $199.0M $202.9M
YoY Change -10.18% 0.09%
Operating Profit -$113.5M -$119.6M
YoY Change -21.48% -8.21%
Interest Expense $644.0K $70.08M
YoY Change 0.0% 10765.43%
% of Operating Profit
Other Income/Expense, Net $16.89M $859.0K
YoY Change -191.82% 127.25%
Pretax Income -$85.61M -$72.28M
YoY Change -47.11% -68.44%
Income Tax $490.0K $496.0K
% Of Pretax Income
Net Earnings -$86.10M -$72.77M
YoY Change -46.85% -68.28%
Net Earnings / Revenue -60.2% -53.06%
Basic Earnings Per Share -$0.73 -$0.67
Diluted Earnings Per Share -$0.73 -$0.67
COMMON SHARES
Basic Shares Outstanding 117.7M shares 102.8M shares
Diluted Shares Outstanding 117.7M shares 108.8M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.155B $1.225B
YoY Change 20.54% 43.48%
Cash & Equivalents $457.3M $271.1M
Short-Term Investments $697.5M $953.8M
Other Short-Term Assets $26.20M $25.81M
YoY Change 11.18% -8.75%
Inventory $77.04M $60.53M
Prepaid Expenses
Receivables $88.80M $86.47M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.347B $1.398B
YoY Change 19.1% 34.76%
LONG-TERM ASSETS
Property, Plant & Equipment $147.7M $321.0M
YoY Change -12.1% 96.5%
Goodwill $3.290M $3.290M
YoY Change 0.0% 0.0%
Intangibles $9.670M $10.36M
YoY Change -22.12% -20.96%
Long-Term Investments
YoY Change
Other Assets $128.0M $107.7M
YoY Change 147.52% 52.63%
Total Long-Term Assets $450.3M $442.4M
YoY Change -21.12% -45.83%
TOTAL ASSETS
Total Short-Term Assets $1.347B $1.398B
Total Long-Term Assets $450.3M $442.4M
Total Assets $1.797B $1.840B
YoY Change 5.61% -0.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $77.83M $79.78M
YoY Change 90.24% 115.8%
Accrued Expenses $205.3M $108.9M
YoY Change 223.93% 41.16%
Deferred Revenue $21.49M $12.24M
YoY Change 60.06% -18.17%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $226.8M $200.9M
YoY Change 29.48% 19.78%
LONG-TERM LIABILITIES
Long-Term Debt $1.139B $1.139B
YoY Change 0.22% 0.23%
Other Long-Term Liabilities $10.18M $207.7M
YoY Change 45.71% 2136.24%
Total Long-Term Liabilities $10.18M $1.346B
YoY Change 45.71% 14397.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $226.8M $200.9M
Total Long-Term Liabilities $10.18M $1.346B
Total Liabilities $1.569B $1.547B
YoY Change 2.21% 0.82%
SHAREHOLDERS EQUITY
Retained Earnings -$1.955B -$1.869B
YoY Change 28.4% 37.36%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $228.3M $292.7M
YoY Change
Total Liabilities & Shareholders Equity $1.797B $1.840B
YoY Change 5.61% -0.74%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$86.10M -$72.77M
YoY Change -46.85% -68.28%
Depreciation, Depletion And Amortization $10.30M $10.63M
YoY Change 13.19% 31.25%
Cash From Operating Activities -$77.79M -$94.01M
YoY Change -0.47% -16.01%
INVESTING ACTIVITIES
Capital Expenditures $2.370M $6.513M
YoY Change -110.91% -128.28%
Acquisitions
YoY Change
Other Investing Activities $263.1M -$234.6M
YoY Change 317.59% 370.55%
Cash From Investing Activities $260.7M -$241.1M
YoY Change 531.63% 230.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.810M 383.9M
YoY Change -119.73% -323.06%
NET CHANGE
Cash From Operating Activities -77.79M -94.01M
Cash From Investing Activities 260.7M -241.1M
Cash From Financing Activities 3.810M 383.9M
Net Change In Cash 186.7M 48.71M
YoY Change -432.25% -113.65%
FREE CASH FLOW
Cash From Operating Activities -$77.79M -$94.01M
Capital Expenditures $2.370M $6.513M
Free Cash Flow -$80.16M -$100.5M
YoY Change 42.04% 13.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117662134 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117662134 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21131000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
381369000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6697000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4116000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22354000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3681000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-72771000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
292726000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
533040000 usd
CY2022Q2 gh Adjustments To Additional Paid In Capital Tender Offer Issued
AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued
9832000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5947000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-229432000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
319087000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
60180000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21131000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
381369000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
220000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6697000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5109000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
44620000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11053000 usd
us-gaap Net Income Loss
NetIncomeLoss
-206304000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
645005000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2157000 usd
gh Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
8000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5742000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2179000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50343000 usd
gh Adjustments To Additional Paid In Capital Tender Offer Issued
AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued
9832000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19497000 usd
us-gaap Net Income Loss
NetIncomeLoss
-352660000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
319087000 usd
us-gaap Net Income Loss
NetIncomeLoss
-206304000 usd
us-gaap Net Income Loss
NetIncomeLoss
-352660000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20976000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15986000 usd
gh Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
14708000 usd
gh Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
14197000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
10000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3805000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
44620000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
50343000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1287000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1284000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3085000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3800000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
67879000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
0 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
29054000 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 usd
gh Fair Value Adjustments Of Noncontrolling Interest Liability
FairValueAdjustmentsOfNoncontrollingInterestLiability
0 usd
gh Fair Value Adjustments Of Noncontrolling Interest Liability
FairValueAdjustmentsOfNoncontrollingInterestLiability
-99785000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-98000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-20000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10695000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2355000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8931000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
29218000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
891000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23670000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1700000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4301000 usd
gh Increase Decrease In Accounts Payable Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities
16512000 usd
gh Increase Decrease In Accounts Payable Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities
22424000 usd
gh Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-14970000 usd
gh Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-6595000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6056000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5949000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-168456000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-140554000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
561339000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
238601000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
492700000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
335000000 usd
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
1227000 usd
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
12750000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45734000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83903000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37915000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
37000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
35000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2158000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5109000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2179000 usd
gh Payments For Joint Venture Acquisition Financing Activities
PaymentsForJointVentureAcquisitionFinancingActivities
0 usd
gh Payments For Joint Venture Acquisition Financing Activities
PaymentsForJointVentureAcquisitionFinancingActivities
177785000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
402500000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21271000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
383000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-172099000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1415000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2211000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
129226000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-276949000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
141948000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
492288000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
271174000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
215339000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1964000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4073000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2151000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16901000 usd
gh Noncash Tender Offer Issued
NoncashTenderOfferIssued
0 usd
gh Noncash Tender Offer Issued
NoncashTenderOfferIssued
9688000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
271073000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
215169000 usd
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
101000 usd
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
170000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
271174000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
215339000 usd
CY2022Q4 gh Number Of Patients
NumberOfPatients
20000 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. </span></div>The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
100000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
300000 usd
CY2023Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
4200000 usd
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
25000000 usd
CY2023Q2 gh Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
16600000 usd
gh Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
22100000 usd
CY2022Q3 gh Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
5300000 usd
CY2023Q2 gh Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
7000000 usd
gh Equity Security Fvni Impairment Or Adjustments To Carrying Value
EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div>The Company is also subject to credit risk from its other receivables and other assets.
CY2020Q3 gh Contractual Receivables Before Allowance For Credit Loss
ContractualReceivablesBeforeAllowanceForCreditLoss
8000000 usd
CY2020Q3 gh Contractual Receivables Term
ContractualReceivablesTerm
P6Y
CY2020Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1000000 usd
CY2021Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1100000 usd
CY2022Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1100000 usd
gh Contractual Receivables Credit Loss Expense Reversal Noncurrent
ContractualReceivablesCreditLossExpenseReversalNoncurrent
4800000 usd
CY2023Q2 gh Contractual Receivables Before Allowance For Credit Loss Gross Current
ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
1100000 usd
CY2022Q4 gh Contractual Receivables Before Allowance For Credit Loss Gross Current
ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
0 usd
CY2023Q2 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 usd
CY2023Q2 gh Contractual Receivables After Allowance For Credit Loss Net Current
ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
0 usd
CY2022Q4 gh Contractual Receivables After Allowance For Credit Loss Net Current
ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
0 usd
CY2023Q2 gh Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent
ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
3700000 usd
CY2022Q4 gh Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent
ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
4800000 usd
CY2023Q2 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
3700000 usd
CY2023Q2 gh Contractual Receivables After Allowance For Credit Loss Net Noncurrent
ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
0 usd
CY2022Q4 gh Contractual Receivables After Allowance For Credit Loss Net Noncurrent
ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
0 usd
CY2023Q2 gh Contractual Receivables Allowance For Credit Loss Period Increase Decrease
ContractualReceivablesAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2022Q2 gh Contractual Receivables Allowance For Credit Loss Period Increase Decrease
ContractualReceivablesAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2022Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 usd
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 usd
gh Contractual Receivables Credit Loss Reclassification Current
ContractualReceivablesCreditLossReclassificationCurrent
1100000 usd
gh Contractual Receivables Credit Loss Reclassification Current
ContractualReceivablesCreditLossReclassificationCurrent
1100000 usd
CY2023Q2 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 usd
CY2022Q2 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 usd
CY2022Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
4800000 usd
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
5900000 usd
gh Contractual Receivables Credit Loss Reclassification Noncurrent
ContractualReceivablesCreditLossReclassificationNoncurrent
-1100000 usd
gh Contractual Receivables Credit Loss Reclassification Noncurrent
ContractualReceivablesCreditLossReclassificationNoncurrent
-1100000 usd
CY2023Q2 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
3700000 usd
CY2022Q2 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
4800000 usd
CY2023Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4400000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
5400000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2023Q2 gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
500000 usd
CY2022Q2 gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
200000 usd
gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
1100000 usd
gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
2300000 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
15100000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
21200000 usd
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2900000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3800000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
11800000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5300000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
263210000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
256051000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
107469000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
88131000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155741000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
167920000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
9900000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
8100000 usd
us-gaap Depreciation
Depreciation
19600000 usd
us-gaap Depreciation
Depreciation
14800000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
79784000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
68911000 usd
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
45775000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
55788000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24707000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21878000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38430000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29240000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
188696000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
175817000 usd
CY2023Q2 gh Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
1163763000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
117000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4419000 usd
CY2023Q2 gh Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
1159461000 usd
CY2022Q4 gh Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
904446000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16779000 usd
CY2022Q4 gh Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
887675000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
135853000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
142000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
389224000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
4277000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
525077000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
4419000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
170975000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2958000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
685754000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
13821000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
856729000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
16779000 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2023Q2 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2022Q2 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
18586000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8225000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10361000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
3290000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
3290000 usd
CY2023Q2 gh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
21876000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8225000 usd
CY2023Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
13651000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
18586000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11727000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
3290000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
3290000 usd
CY2022Q4 gh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
21876000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6859000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
15017000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1381000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2219000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1670000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1212000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1107000 usd
CY2023Q2 gh Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
2772000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10361000 usd
CY2020Q4 gh Convertible Debt Hedge Strike Price
ConvertibleDebtHedgeStrikePrice
182.60
CY2020Q4 gh Convertible Debt Hedge Share Price Premium Percentage
ConvertibleDebtHedgeSharePricePremiumPercentage
0.75
CY2020Q4 us-gaap Share Price
SharePrice
104.34
CY2020Q4 gh Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges
90000000 usd
CY2023Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
7400000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
7200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
14700000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
14200000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0389
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0393
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
16027000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
33582000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
32605000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
27776000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
24479000 usd
CY2023Q2 gh Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
125157000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
259626000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36689000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
222937000 usd
us-gaap Dividends Common Stock
DividendsCommonStock
0 usd
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0 usd
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20296252 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16249546 shares
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14375000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108808000 shares
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
28.00
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
381400000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21100000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5438296 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3402574 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39749000 usd
gh Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
3689000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
296462 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
32.18
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
31879 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
98473 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
67.61
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8920920 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3568684 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
55487000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2232274 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
53053000 usd
CY2023Q1 gh Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
3689000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
20.90
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
20.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.67
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39600000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102047000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102047000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105752000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105752000 shares
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22354000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25544000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44620000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50343000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72771000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72771000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-229432000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-229432000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-206304000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-206304000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-352660000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-352660000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.46
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108808000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101950000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101950000 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17815000 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15272000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17915000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15116000 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Revenues
Revenues
137150000 usd
CY2022Q2 us-gaap Revenues
Revenues
109144000 usd
us-gaap Revenues
Revenues
265864000 usd
us-gaap Revenues
Revenues
205243000 usd

Files In Submission

Name View Source Status
0001576280-23-000123-index-headers.html Edgar Link pending
0001576280-23-000123-index.html Edgar Link pending
0001576280-23-000123.txt Edgar Link pending
0001576280-23-000123-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gh-06302023x10qxex101.htm Edgar Link pending
gh-06302023x10qxex311.htm Edgar Link pending
gh-06302023x10qxex312.htm Edgar Link pending
gh-06302023x10qxex313.htm Edgar Link pending
gh-06302023x10qxex321.htm Edgar Link pending
gh-06302023x10qxex322.htm Edgar Link pending
gh-06302023x10qxex323.htm Edgar Link pending
gh-20230630.htm Edgar Link pending
gh-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
gh-20230630_cal.xml Edgar Link unprocessable
gh-20230630_def.xml Edgar Link unprocessable
gh-20230630_lab.xml Edgar Link unprocessable
gh-20230630_pre.xml Edgar Link unprocessable
gh-20230630_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable